Skip to main content
. 2021 Oct 27;4(10):e2131744. doi: 10.1001/jamanetworkopen.2021.31744

Figure 1. Comparison of Study Design and Eligibility Characteristics of Trials That Began Enrollment Between 2000 and 2009 or Between 2010 and 2020.

Figure 1.

GI indicates gastrointestinal; ICI, immune checkpoint inhibitor; NECs, neuroendocrine carcinomas; NEN, neuroendocrine neoplasm; NETs, neuroendocrine tumors, NR, non-randomized; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RPI, receptor pathway inhibitor; SSA, somatostatin analog; and VEGF, vascular endothelial growth factor.

aStatistically significant difference between the enrollment periods.